Nitrazepam
Sleep Disorder, Initiating And Maintaining Sleep
Explore 1 assets in Sleep Disorder, Initiating And Maintaining Sleep →Floatz Rating
B56/100
Confidence
Indicative
Sponsor
Astellas Pharma Inc
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
41Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00374777CT.gov A Double-blind, Group-comparison P-III Study With Zolpidem MR Using Placebo and Nitrazepam in Insomnia Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Sleep Disorder, Initiating And Maintaining Sleep
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nitrazepam (this asset) | Astellas Pharma Inc | P3 | B · 56 |
| (±)-Ftc | Azienda Ospedaliera San Gerardo di Monza | P4 | BB |
| Zolpidem | Astellas Pharma Inc | P3 | BB |
| fk199b | Astellas Pharma Inc | P3 | BB |
| Suvorexant | Merck Sharp & Dohme LLC | P3 | BB |
| Tenofovir Disoproxil Fumarate | Azienda Ospedaliera San Gerardo di Monza | P4 | B |
| Modafinil | VA Palo Alto Health Care System | P4 | B |
| Tiaoshen Anti-Cancer Granules | Shanghai Municipal Hospital of Traditional Chinese Medicine | P2/3 | B |
| Cyclobenzaprine | Lynn Henry | P2 | CCC |
+4 more in the Sleep Disorder, Initiating And Maintaining Sleep cohort
Other indications for Nitrazepam
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Anxiety Disorder | — | P3 | CCC · 54 |
| Physiological Malfunction Arising From Mental Factor | — | P3 | CCC · 54 |
| Dementia | — | P3 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nitrazepam in Sleep Disorder, Initiating And Maintaining Sleep. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nitrazepam-sleep-disorder-initiating-and-maintaining-sleep
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →